Anglo-Swedish pharma major AstraZeneca has confirmed that its chief medical officer, Briggs Morrison, has decided to leave his post, which he has held since 2012, joining the company from Pfizer.
Dr Morrison will be “leaving in a matter of weeks,” the company said. He has apparently taken up the position of chief executive of a small, privately owned biotech company whose identity has not been revealed, in a move that surprised industry watchers.
AstraZeneca’s chief executive, Pascal Soriot, will take over responsibility for late-stage drug development on an interim basis, while Elisabeth Björk, an associate professor of medicine at Uppsala University, Sweden, who leads cardiovascular and metabolic drug development at AstraZeneca, becomes acting chief medical officer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze